ArticlePloS one2019
A novel sequencing-based vaginal health assay combining self-sampling, HPV detection and genotyping, STI detection, and vaginal microbiome analysis.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 50 citations in OpenAlex.
- Trial
- Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota.PloS one · 2021Trial
- Cervicovaginal microbiome and natural history of HPV in a longitudinal study.PLoS pathogens · 2020Trial
- The interplay between HPV, vaginal microbiota and host immunity in cervical carcinogenesis.Discover oncology · 2026Review
- Cervical cancer patients' vaginal microbiome and metabolites: research progress and clinical applications.Frontiers in microbiology · 2026Review
- Metagenomic insight into the vaginal microbiome in women infected with HPV 16 and 18.NPJ biofilms and microbiomes · 2025Article
- Article
- Revolutionizing Cervical Cancer Screening: Self-Vaginal Sampling for Human Papillomavirus Detection.South Asian journal of cancer · 2025Article
- Effects of variation in sample storage conditions and swab order on 16S vaginal microbiome analyses.Microbiology spectrum · 2024Article
- Integration of 168,000 samples reveals global patterns of the human gut microbiome.bioRxiv : the preprint server for biology · 2023Article
- Pre- and post-LEEP: analysis of the female urogenital tract microenvironment and its association with sexual dysfunction.Sexual medicine · 2023Article
- Microbiota Profile of the Nasal Cavity According to Lifestyles in Healthy Adults in Santiago, Chile.Microorganisms · 2023Article
- Review
- Comprehensive characterization of maternal, fetal, and neonatal microbiomes supports prenatal colonization of the gastrointestinal tract.Scientific reports · 2023Article
- High risk HPV-positive women cervicovaginal microbial profiles in a Greek cohort: a retrospective analysis of the GRECOSELF study.Frontiers in microbiology · 2023Article
- HPV genotyping by L1 amplicon sequencing of archived invasive cervical cancer samples: a pilot study.Infectious agents and cancer · 2022Article
- Implications of Gut Microbiota in Epithelial-Mesenchymal Transition and Cancer Progression: A Concise Review.Cancers · 2022Review
- Role of Immunity and Vaginal Microbiome in Clearance and Persistence of Human Papillomavirus Infection.Frontiers in cellular and infection microbiology · 2022Review
- Article
- Probiotics and prebiotics potential for the care of skin, female urogenital tract, and respiratory tract.Folia microbiologica · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The composition of the vaginal microbiome, including both the presence of pathogens involved in sexually transmitted infections (STI) as well as commensal microbiota, has been shown to have important associations for a woman's reproductive and general health. Currently, healthcare providers cannot offer comprehensive vaginal microbiome screening, but are limited to the detection of individual pathogens, such as high-risk human papillomavirus (hrHPV), the predominant cause of cervical cancer. There is no single test on the market that combines HPV, STI, and microbiome screening. Here, we describe a novel inclusive vaginal health assay that combines self-sampling with sequencing-based HPV detection and genotyping, vaginal microbiome analysis, and STI-associated pathogen detection. The assay includes genotyping and detection of 14 hrHPV types, 5 low-risk HPV types (lrHPV), as well as the relative abundance of 31 bacterial taxa of clinical importance, including Lactobacillus, Sneathia, Gardnerella, and 3 pathogens involved in STI, with high sensitivity, specificity, and reproducibility. For each of these taxa, reference ranges were determined in a group of 50 self-reported healthy women. The HPV sequencing portion of the test was evaluated against the digene High-Risk HPV HC2 DNA test. For hrHPV genotyping, agreement was 95.3% with a kappa of 0.804 (601 samples); after removal of samples in which the digene hrHPV probe showed cross-reactivity with lrHPV types, the sensitivity and specificity of the hrHPV genotyping assay were 94.5% and 96.6%, respectively, with a kappa of 0.841. For lrHPV genotyping, agreement was 93.9% with a kappa of 0.788 (148 samples), while sensitivity and specificity were 100% and 92.9%, respectively. This novel assay could be used to complement conventional cervical cancer screening, because its self-sampling format can expand access among women who would otherwise not participate, and because of its additional information about the composition of the vaginal microbiome and the presence of pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.